Differences in medication adherence by sex and organ type among adolescent and young adult solid organ transplant recipients.
medication adherence
sex
solid organ transplantation
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
26
10
2022
received:
22
06
2022
accepted:
11
11
2022
pubmed:
9
12
2022
medline:
11
2
2023
entrez:
8
12
2022
Statut:
ppublish
Résumé
Identification of differences in medication adherence by sex or organ type may help in planning interventions to optimize outcomes. We compared immunosuppressive medication adherence between males and females, and between kidney, liver and heart transplant recipients. This multicenter study of prevalent kidney, liver and heart transplant recipients 14-25 years assessed adherence 3 times (0, 3, 6 months post-enrollment) with the BAASIS self-report tool. At each visit, participants were classified as adherent if they missed no doses in the prior 4 weeks and non-adherent otherwise. Adherence was also assessed using the coefficient of variation (CV) of tacrolimus trough levels; CV < 30% was classified as adherent. We used multivariable mixed effects logistic regression models adjusted for potential confounders to compare adherence by sex and by organ. Across all visits, males (n = 150, median age 20.4 years, IQR 17.2-23.3) had lower odds of self-reported adherence than females (n = 120, median age 19.8 years, IQR 17.1-22.7) (OR 0.41, 95% CI 0.21-0.80) but higher odds of adherence by tacrolimus CV (OR 2.50, 95% CI 1.30-4.82). No significant differences in adherence (by self-report or tacrolimus CV) were noted between the 184 kidney, 58 liver, and 28 heart recipients. Females show better self-reported adherence than males but greater variability in tacrolimus levels. Social desirability bias, more common in females than males, may contribute to better self-reported adherence among females. Higher tacrolimus variability among females may reflect biologic differences in tacrolimus metabolism between males and females rather than sex differences in adherence. There were no significant differences in adherence by organ type.
Sections du résumé
BACKGROUND
Identification of differences in medication adherence by sex or organ type may help in planning interventions to optimize outcomes. We compared immunosuppressive medication adherence between males and females, and between kidney, liver and heart transplant recipients.
METHODS
This multicenter study of prevalent kidney, liver and heart transplant recipients 14-25 years assessed adherence 3 times (0, 3, 6 months post-enrollment) with the BAASIS self-report tool. At each visit, participants were classified as adherent if they missed no doses in the prior 4 weeks and non-adherent otherwise. Adherence was also assessed using the coefficient of variation (CV) of tacrolimus trough levels; CV < 30% was classified as adherent. We used multivariable mixed effects logistic regression models adjusted for potential confounders to compare adherence by sex and by organ.
RESULTS
Across all visits, males (n = 150, median age 20.4 years, IQR 17.2-23.3) had lower odds of self-reported adherence than females (n = 120, median age 19.8 years, IQR 17.1-22.7) (OR 0.41, 95% CI 0.21-0.80) but higher odds of adherence by tacrolimus CV (OR 2.50, 95% CI 1.30-4.82). No significant differences in adherence (by self-report or tacrolimus CV) were noted between the 184 kidney, 58 liver, and 28 heart recipients.
CONCLUSION
Females show better self-reported adherence than males but greater variability in tacrolimus levels. Social desirability bias, more common in females than males, may contribute to better self-reported adherence among females. Higher tacrolimus variability among females may reflect biologic differences in tacrolimus metabolism between males and females rather than sex differences in adherence. There were no significant differences in adherence by organ type.
Substances chimiques
Tacrolimus
WM0HAQ4WNM
Immunosuppressive Agents
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14446Subventions
Organisme : CIHR
Pays : Canada
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Lepeytre F, Dahhou M, Zhang X, et al. Association of sex with risk of kidney graft failure differs by age. J. Am. Soc. Nephrol. 2017;28(10):3014-3023. doi:10.1681/ASN.2016121380
Nguyen LS, Coutance G, Salem JE, et al. Effect of recipient gender and donor-specific antibodies on antibody-mediated rejection after heart transplantation. Am. J. Transplant. 2019;19(4):1160-1167. doi:10.1111/ajt.15133
Heidari S, Babor TF, de Castro P, Tort S, Curno M. Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev. 2016;1(1):2. doi:10.1186/s41073-016-0007-6
Krieger N. Genders, sexes, and health: what are the connections - and why does it matter? Int. J. Epidemiol. 2003;32(4):652-657. doi:10.1093/ije/dyg156
Gokoel SRM, Gombert-Handoko KB, Zwart TC, van der Boog PJM, Moes DJAR, de Fijter JW. Medication non-adherence after kidney transplantation: a critical appraisal and systematic review. Transplant. Rev. 2020;34(1):100511. doi:10.1016/j.trre.2019.100511
Belaiche S, Décaudin B, Dharancy S, Noel C, Odou P, Hazzan M. Factors relevant to medication non-adherence in kidney transplant: a systematic review. Int. J. Clin. Pharmacol. 2017;39(3):582-593. doi:10.1007/s11096-017-0436-4
Chisholm-Burns MA, Spivey CA, Tolley EA, Kaplan EK. Medication therapy management and adherence among US renal transplant recipients. Patient Prefer. Adherence. 2016;10:703-709. doi:10.2147/PPA.S104646
Dharancy S, Giral M, Tetaz R, Fatras M, Dubel L, Pageaux GP. Adherence with immunosuppressive treatment after transplantation: results from the French trial PREDICT. Clin. Transpl. 2012;26(3):293-299. doi:10.1111/j.1399-0012.2012.01652.x
Weng LC, Yang YC, Huang HL, Chiang YJ, Tsai YH. Factors that determine self-reported immunosuppressant adherence in kidney transplant recipients: a correlational study. J. Adv. Nurs. 2017;73(1):228-239. doi:10.1111/jan.13106
Germani G, Lazzaro S, Gnoato F, et al. Nonadherent behaviors after solid organ transplantation. Transplant. Proc. 2011;43(1):318-323. doi:10.1016/j.transproceed.2010.09.103
Connelly J, Pilch N, Oliver M, et al. Prediction of medication non-adherence and associated outcomes in pediatric kidney transplant recipients. Pediatr. Transplant. 2015;19(5):555-562. doi:10.1111/petr.12479
Beck DE, Fennell RS, Yost RL, Robinson JD, Geary D, Richards GA. Evaluation of an educational program on compliance with medication regimens in pediatric patients with renal transplants. J. Pediatr. 1980;96(6):1094-1097. doi:10.1016/s0022-3476(80)80653-6
Berquist RK, Berquist WE, Esquivel CO, Cox KL, Wayman KI, Litt IF. Adolescent non-adherence: Prevalence and consequences in liver transplant recipients. Pediatr. Transplant. 2006;10(3):304-310. doi:10.1111/j.1399-3046.2005.00451.x
Denhaerynck K, Berben L, Dobbels F, et al. Multilevel factors are associated with immunosuppressant nonadherence in heart transplant recipients: the international BRIGHT study. Am. J. Transplant. 2018;18(6):1447-1460. doi:10.1111/ajt.14611
de Geest S, Burkhalter H, Bogert L, Berben L, Glass TR, Denhaerynck K. Describing the evolution of medication nonadherence from pretransplant until 3 years post-transplant and determining pretransplant medication nonadherence as risk factor for post-transplant nonadherence to immunosuppressives: the Swiss transplant cohort study. Transpl. Int. 2014;27(7):657-666. doi:10.1111/tri.12312
Dew MA, DiMartini AF, de Vito DA, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83(7):858-873. doi:10.1097/01.tp.0000258599.65257.a6
Dew MA, Dabbs AD, Myaskovsky L, et al. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation. 2009;88(5):736-746. doi:10.1097/TP.0b013e3181b2a0e0
Shemesh E, Duncan S, Anand R, et al. Trajectory of adherence behavior in pediatric and adolescent liver transplant recipients: the medication adherence in children who had a liver transplant cohort. Liver Transpl. 2018;24(1):80-88. doi:10.1002/lt.24837
Fewell Z, Davey Smith G, Sterne JAC. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am. J. Epidemiol. 2007;166(6):646-655. doi:10.1093/aje/kwm165
Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am. J. Epidemiol. 2013;177(4):292-298. doi:10.1093/aje/kws412
Foster BJ, Dahhou M, Zhang X, Platt RW, Samuel SM, Hanley JA. Association between age and graft failure rates in young kidney transplant recipients. Transplantation. 2011;92(11):1237-1243. doi:10.1097/TP.0b013e31823411d7
Foster BJ, Dahhou M, Zhang X, Dharnidharka VR, Conway J, Ng VL. High risk of liver allograft failure during late adolescence and young adulthood. Transplantation. 2016;100(3):577-584. doi:10.1097/TP.0000000000001009
Foster BJ, Dahhou M, Zhang X, Dharnidharka V, Ng V, Conway J. High risk of graft failure in emerging adult heart transplant recipients. Am. J. Transplant. 2015;15(12):3185-3193. doi:10.1111/ajt.13386
Jiang Y, Que W, Zhu P, Li XK. The role of diverse liver cells in liver transplantation tolerance. Front. Immunol. 2020;11:11. doi:10.3389/fimmu.2020.01203
Levitsky J. Does the liver provide immunosuppressive advantage? Clin Liver Dis (Hoboken). 2019;13(6):180-183. doi:10.1002/cld.817
Morales JM, Varo E, Lázaro P. Immunosuppressant treatment adherence, barriers to adherence and quality of life in renal and liver transplant recipients in Spain. Clin. Transpl. 2012;26(2):369-376. doi:10.1111/j.1399-0012.2011.01544.x
de Geest S, Ribaut J, Denhaerynck K, Dobbels F. Adherence management in transplantation: creating impact in real world settings based on state of the art evidence. In: Cukor D, Cohen S, Kimmel PL, eds. Psychosocial aspects of chronic kidney disease. Exploring the impact of CKD, dialysis, and transplantation on patients. 1st ed. Elsevier;2021:409-448.
Sankaranarayanan J, Collier D, Furasek A, et al. Rurality and other factors associated with adherence to immunosuppressant medications in community-dwelling solid-organ transplant recipients. Res. Soc. Adm. Pharm. 2012;8(3):228-239. doi:10.1016/j.sapharm.2011.04.001
Kung M, Koschwanez HE, Painter L, Honeyman V, Broadbent E. Immunosuppressant nonadherence in heart, liver, and lung transplant patients: associations with medication beliefs and illness perceptions. Transplantation. 2012;93(9):958-963. doi:10.1097/TP.0b013e31824b822d
de Geest S, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP medication adherence reporting guideline (EMERGE). Ann. Intern. Med. 2018;169(1):30-35. doi:10.7326/M18-0543
Dabirzadeh A, Dahhou M, Zhang X, et al. Care processes and structures associated with higher medication adherence in adolescent and young adult transplant recipients. Pediatr. Transplant. 2021;25(8):1-14. doi:10.1111/petr.14106
Marsicano EDO, Fernandes NDS, Colugnati F, et al. Transcultural adaptation and initial validation of Brazilian-Portuguese version of the Basel assessment of adherence to immunosuppressive medications scale (BAASIS) in kidney transplants. BMC Nephrol. 2013;14(1):1-8. doi:10.1186/1471-2369-14-108
Dobbels F, Berben L, de Geest S, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation. 2010;90(2):205-219. doi:10.1097/TP.0b013e3181e346cd
Lieb M, Hepp T, Schiffer M, Opgenoorth M, Erim Y. Accuracy and concordance of measurement methods to assess non-adherence after renal transplantation - a prospective study. BMC Nephrol. 2020;21(1):1-13. doi:10.1186/s12882-020-01781-1
Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl. Behav. Med. 2015;5(4):470-482. doi:10.1007/s13142-015-0315-2
Gustavsen MT, Midtvedt K, Lønning K, et al. Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation - a single-Centre open prospective trial. Transpl. Int. 2019;32(6):614-625. doi:10.1111/tri.13412
Leino AD, King EC, Jiang W, et al. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: establishing baseline values. Am. J. Transplant. 2019;19(5):1410-1420. doi:10.1111/ajt.15199
Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DRJ. High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients. Am. J. Transplant. 2016;16(10):2954-2963. doi:10.1111/ajt.13803
Pollock-Barziv SM, Finkelstein Y, Manlhiot C, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr. Transplant. 2010;14(8):968-975. doi:10.1111/j.1399-3046.2010.01409.x
Rodrigo E, Segundo DS, Fernández-Fresnedo G, et al. Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development. Transplantation. 2016;100(11):2479-2485. doi:10.1097/TP.0000000000001040
Rayar M, Tron C, Jézéquel C, et al. High Intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes. Transplantation. 2018;102(3):e108-e114. doi:10.1097/TP.0000000000002052
Gueta I, Markovits N, Yarden-Bilavsky H, et al. High tacrolimus trough level variability is associated with rejections after heart transplant. Am. J. Transplant. 2018;18(10):2571-2578. doi:10.1111/ajt.15016
Sanders-Pinheiro H, Colugnati FAB, Denhaerynck K, Marsicano EO, Medina JOP, de Geest S. Multilevel correlates of immunosuppressive nonadherence in kidney transplant patients: the multicenter ADHERE Brazil study. Transplantation. 2021;105(1):255-266. doi:10.1097/TP.0000000000003214
Jarrod E. SAS global forum 2012 statistics and data analysis a unified approach to measuring the effect size between two groups using SAS® Dongsheng Yang and Jarrod E. Dalton Departments of Quantitative Health Sciences and Outcomes Research Cleveland Clinic SAS G; 2012.
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann. Intern. Med. 2007;147(8):W163-W194. doi:10.7326/0003-4819-147-8-200710160-00010-w1
Shemesh E, Fine RN. Is calculating the standard deviation of tacrolimus blood levels the new gold standard for evaluating non-adherence to medications in transplant recipients? Pediatr. Transplant. 2010;14(8):940-943. doi:10.1111/j.1399-3046.2010.01396.x
Myaskovsky L, Jesse MT, Kuntz K, et al. Report from the American Society of Transplantation psychosocial Community of Practice Adherence Task Force: real-world options for promoting adherence in adult recipients. Clin. Transpl. 2018;32(9):e13353. doi:10.1111/ctr.13353
Boucquemont J, Pai ALH, Dharnidharka VR, Hebert D, Furth SL, Foster BJ. Gender differences in medication adherence among adolescent and young adult kidney transplant recipients. Transplantation. 2019;103(4):798-806. doi:10.1097/TP.0000000000002359
Denhaerynck K, Steiger J, Bock A, et al. Prevalence and risk factors of non-adherence with immunosuppressive medication in kidney transplant patients. Am. J. Transplant. 2007;7(1):108-116. doi:10.1111/j.1600-6143.2006.01611.x
Bernardi RA. Associations between Hofstede's cultural constructs and social desirability response bias. J. Bus. Ethics. 2006;65(1):43-53. doi:10.1007/s10551-005-5353-0
Hebert JR, Clemow L, Pbert L, Ockene ISOJ. Social desirability bias in dietary self-report may compromise the validity of dietary intake measures. Int. J. Epidemiol. 1995;24(2):389-398. doi:10.1093/ije/24.2.389
Reese PP, Bloom RD, Trofe-Clark J, et al. Automated reminders and physician notification to promote immunosuppression adherence among kidney transplant recipients: a randomized trial. Am. J. Kidney Dis. 2017;69(3):400-409. doi:10.1053/j.ajkd.2016.10.017
Leino AD, Abuls KM, Rodgers JKL, Kuntz KK. Evaluation of the relationship between medication adherence and tacrolimus coefficient of variation. Progress in Transplantation. 2022;32:189. doi:10.1177/15269248221087440
Foster BJ, Pai ALH, Zelikovsky N, et al. A randomized trial of a multicomponent intervention to promote medication adherence: the teen adherence in kidney transplant effectiveness of intervention trial (TAKE-IT). Am. J. Kidney Dis. 2018;72(1):30-41. doi:10.1053/j.ajkd.2017.12.012
Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant. Rev. 2015;29(2):78-84. doi:10.1016/j.trre.2015.01.002
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 2004;43(10):623-653. doi:10.2165/00003088-200443100-00001
Ro H, Min SI, Yang J, et al. Impact of tacrolimus Intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther. Drug Monit. 2012;34(6):680-685. doi:10.1097/FTD.0b013e3182731809
Pashaee N, Bouamar R, Hesselink DA, et al. CYP3A5 genotype is not related to the Intrapatient variability of tacrolimus clearance. Ther. Drug Monit. 2011;33(3):369-371. doi:10.1097/FTD.0b013e31821a7aa3
Spierings N, Holt DW, MacPhee IA. CYP3A5 genotype had No impact on Intrapatient variability of tacrolimus clearance in renal transplant recipients. Ther. Drug Monit. 2013;35(3):328-331. doi:10.1097/FTD.0b013e318289644d
Iwasaki K, Matsuda H, Nagase K, Shiraga T, Tokuma Y, Uchida K. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res. Commun. Chem. Pathol. Pharmacol. 1993;82(2):209-216.
Satoh T, Munakata H, Fujita KI, et al. Studies on the interactions between drug and estrogen. II.1 on the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17. Biol. Pharm. Bull. 2003;26(5):695-700. doi:10.1248/bpb.26.695
Kuypers DRJ, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin. Pharmacokinet. 2004;43(11):741-762. doi:10.2165/00003088-200443110-00005
Soldin O, Mattison D. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 2009;48(3):143-157. doi:10.2165/00003088-200948030-00001
Ghadimi M, Dashti-Khavidaki S, Shahali M, Gohari M, Khatami MR, Alamdari A. Tacrolimus interaction with oral oestrogen in kidney transplant recipients: a case-control study. J. Clin. Pharm. Ther. 2018;43(4):513-518. doi:10.1111/jcpt.12672
Migali GTM. Interaction between estradiol and tacrolimus in kidney-transplanted menopausal women. NDT Plus. 2008;1(4):277-278. doi:10.1093/ndtplus/sfn035
Spivey CA, Chisholm-Burns MA, Damadzadeh B, Billheimer D. Determining the effect of immunosuppressant adherence on graft failure risk among renal transplant recipients. Clin. Transpl. 2014;28(1):96-104. doi:10.1111/ctr.12283
Chisholm MA, Vollenweider LJ, Mulloy LL, et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation. 2000;70(8):1240-1244. doi:10.1097/00007890-200010270-00020
Nevins TE, Thomas W. Quantitative patterns of azathioprine adherence after renal transplantation. Transplantation. 2009;87(5):711-718. doi:10.1097/TP.0b013e318195c3d5
Taber DJ, Fleming JN, Fominaya CE, et al. The impact of health care appointment non-adherence on graft outcomes in kidney transplantation. Am. J. Nephrol. 2017;45(1):91-98. doi:10.1159/000453554